Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 51407-184

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 51407-184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407 184 05lb

Label for Rabeprazole Sodium delayed-release tablets, 20 mg strength. The label indicates a package size of 500 tablets and includes storage instructions. It is labeled for prescription use only and shows the NDC 51407-184-05. The labeler is Golden State Medical Supply, Inc.*

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of Rabeprazole Sodium showing its molecular arrangement including the sodium atom, sulfur-containing sulfoxide group, and pyridine ring.*

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph comparing mean heartburn scores over 28 days among three groups: Placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg. The y-axis shows mean scores from 0 (none) to 4 (very severe), and the x-axis displays study days from -14 to 28. Scores decrease notably after day 0 for the Rabeprazole 20 mg group compared to placebo and Rabeprazole 10 mg groups.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo, Rabeprazole (RAB) 10 mg, and Rabeprazole 20 mg. The x-axis represents study days, ranging from day -14 to day 28, and the y-axis represents mean heartburn scores from 0 (none) to 4 (very severe). The graph compares the treatment groups' heartburn scores before and after the start of treatment at day 0.*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph comparing mean heartburn scores over a 28-day study period between placebo and Rabeprazole Sodium 20 mg delayed-release tablet groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 to 4, with lower scores indicating less severe heartburn.*

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: placebo (n=58) and Rabeprazole Sodium 20 mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph shows a trend of decreasing heartburn scores over time for both groups, with lower scores in the Rabeprazole group after day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.